A phase I/II study of ALIMTA (pemetrexed) in patients with relapsed or refractory acute leukaemia or lymphoid blast phase CML [chronic myeloid leukaemia]

Trial Profile

A phase I/II study of ALIMTA (pemetrexed) in patients with relapsed or refractory acute leukaemia or lymphoid blast phase CML [chronic myeloid leukaemia]

Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 23 Jan 2006

At a glance

  • Drugs Pemetrexed (Primary)
  • Indications Leukaemia
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 23 Jan 2006 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top